Reset filters
  • 27 October 2008

Darunavir effective and tolerable in treatment-experienced children and adolescents at 48 weeks

Read the article
  • 27 October 2008

Bevirimat: good results at 400 mg liquid dose, but formulation problems persist

Read the article
  • 27 October 2008

No significant differences between elvucitabine and 3TC at 48 weeks

Read the article
  • 27 October 2008

Raltegravir non-inferior to efavirenz: 48 week, phase III results

Read the article
  • 22 October 2008

Once-daily darunavir (Prezista) approved for first-line use in United States

Read the article
  • 17 October 2008

Maraviroc fails to make economic case for use by NHS in Scotland

Read the article
  • 22 September 2008

New maturation inhibitor ready for trials in HIV-positive patients

Read the article
  • 11 September 2008

Herpes drug has direct anti-HIV effect, could offer cheap addition to antiretroviral therapy for developing world

Read the article
  • 5 September 2008

Brazil rejects tenofovir patent

Read the article

Receive the latest HIV research and conference news

Complete this form to receive regular email bulletins including the latest HIV research and conference news from aidsmap and/or updates from Terrence Higgins Trust.

Get regular email bulletins

Please let us know how you'd like to be contacted by ticking the options below.